Spyre Therapeutics (NASDAQ: SYRE) is a biotechnology company developing treatments for inflammatory bowel disease. The company is currently focused on its drug candidate, SPY001, which is being tested as a potential treatment for moderate-to-severe ulcerative colitis, a chronic inflammatory condition affecting the large intestine.
Following positive trial results, Deutsche Bank raises its price target on Spyre Therapeutics to $88.00, a significant increase from its previous target of $55.00. This new target suggests a potential upside of approximately 39.09% from the stock's price of $63.27 at the time of the announcement.
The analyst's confidence comes after Spyre Therapeutics announced successful results from its Phase 2 SKYLINE trial. As highlighted by GlobeNewswire, the trial met its primary goal. It showed a statistically significant 9.2-point reduction in the Robart's Histopathology Index (RHI) score, a measure of disease activity, at week 12.
The trial also achieved key secondary goals, with 40% of patients reaching clinical remission and 51% showing endoscopic improvement. Benzinga highlights that this positive data has caused the stock to trade higher. The company reports that SPY001 was well-tolerated by patients during the study.
The market has reacted strongly to the news. The stock's price has risen by 23.36% in a single day, reaching a new 52-week high of $75.00. The company's market capitalization, which is the total value of all its shares, now stands at approximately $3.82 billion.
